Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

Jaguar’s requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia® A ...
Fox 5 San Diego

Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

Company's Canalevia ®-CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to ...
recordonline

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia’s Indication to Treatment of General Diarrhea in Dogs

“Specifically, our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in ...
Nasdaq

Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Canalevia™-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / January 4, 2022 / Jaguar Health ...
The Journal News

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia’s Indication to Treatment of General Diarrhea in Dogs

Jaguar plans to submit a dossier to the European Medicines Agency (EMA) to outline the results of the updated analysis of the company’s completed study of Canalevia in dogs with general diarrhea. If ...